Axsome Therapeutics announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder in adults. FOCUS is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol or placebo for 6 weeks. The primary endpoint will be change in the Adult ADHD Investigator Symptom Report Scale.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
- Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
- Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
- Axsome Therapeutics prices 3M shares at $75.00 in public offering
- Axsome Therapeutics Announces Proposed Public Offering of Common Stock